Persistent Pulmonary Hypertension of the Newborn
Status: | Completed |
---|---|
Conditions: | High Blood Pressure (Hypertension) |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 3/1/2014 |
Start Date: | December 2011 |
End Date: | August 2013 |
Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)
The AC-052-391-study is a phase 3 study to investigate whether adding bosentan to inhaled
nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a
supporting and safe therapy.
nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a
supporting and safe therapy.
Inclusion Criteria:
1. Signed informed consent by the parent(s) or the legal representative(s).
2. Term and near term newborns (gestational age > 34 weeks).
3. Post natal age ≥ 12 hours and < 7 days.
4. Weight at birth ≥ 2,500 g.
5. Idiopathic PPHN or PPHN due to parenchymal lung disease
6. Pulmonary hypertension (PH) confirmed by echocardiography:
7. Need for continued iNO at a dose > 10ppm after at least 4 hours of continuous iNO
treatment.
8. Two oxygenation index (OI) values ≥ 15 taken at least 30 minutes apart, in the 12
hours prior to randomization and while the patient is receiving iNO treatment.
9. Mechanical ventilation with fraction of inspired oxygen (FiO2) ≥ 50%.
Exclusion Criteria:
1. PH associated with conditions other than PPHN.
2. Immediate need for cardiac resuscitation or extracorporeal membrane oxygenation
(ECMO) (profound hypoxemia [PaO2] < 30 mm Hg; OI > 40).
3. Lethal congenital anomalies.
4. Congenital Diaphragmatic Hernia.
5. Significant congenital heart disease or significant left to right shunt.
6. Medically significant pneumothorax.
7. Active seizures.
8. Expected duration of mechanical ventilation of less than 48 hours.
9. Mean systemic blood pressure < 35 mmHg despite therapy with volume infusions and
cardiotonic support.
10. Hepatic failure or all conditions with either AST or ALT values > 2 x ULN.
11. Renal function impairment such as serum creatinine > 3 x ULN or anuria.
12. Known intracranial hemorrhage grade III or IV.
13. Either hemoglobin or hematocrit level < 75% of the LLN.
14. Thrombocytopenia (platelet count < 50,000 cells /µL).
15. Leukopenia (WBC < 2,500 cells/ µL).
16. Any condition precluding the use of a nasogastric/orogastric tube.
17. Administration of prohibited medication prior to randomization.
We found this trial at
5
sites
225 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials